Evidence map›Paper›PMID 38343657›Full record

ArticleBiomedical reports2024

Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.

Alexander M Scherbakov, Danila V Sorokin, Valeria E Razuvaeva, Yuri Yu Shchegolev, Olga E Andreeva, Diana I Salnikova, Timur I Fetisov, Olga A Vlasova, Kirill I Kirsanov, Margarita V Gudkova and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Alexander M ScherbakovDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Danila V SorokinDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Valeria E RazuvaevaDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Yuri Yu ShchegolevDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Olga E AndreevaDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Diana I SalnikovaDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Timur I FetisovDepartment of Chemical Carcinogenesis, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Olga A VlasovaDepartment of Chemical Carcinogenesis, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Kirill I KirsanovDepartment of Chemical Carcinogenesis, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Margarita V GudkovaDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Mikhail A Krasil'nikovDepartment of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, The Ministry of Health of Russia, Moscow 115522, Russian Federation.
Ministry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining chemotherapy and hormone therapy is a prevalent approach in breast cancer treatment. While the cytotoxic impact of numerous chemotherapy drugs stems from DNA damage, the exact role of these DNA alterations in modulating estrogen receptor α (ERα) machinery remains elusive. The present study aimed to analyze the impact of DNA damage agents on ERα signaling in breast cancer cells and assess the signaling pathways mediating the influence of DNA damage drugs on the ERα machinery. Cell viability was assessed using the MTT method, while the expression of signaling proteins was analyzed by immunoblotting. ERα activity in the cells treated with various drugs (17β-estradiol, tamoxifen, 5-fluorouracil) was assessed through reporter gene assays.

Indexed as

5-fluorouracilbreast cancerDNA damageestrogen receptor αprogressionresistancetamoxifenultraviolet C irradiation

Identifiers

PMID38343657
PMCPMC10853760
OpenAlexW4391031296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.